 DURHAM, N.C.--BUSINESS WIRE--- DTIL ARCUS--Precision BioSciences, Inc. Nasdaq: DTIL, a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that four abstracts, including one from a research and license collaboration, were accepted by the American Society of Gene Cell Therapy ASGCT and will be presented as posters and oral presentations at the upcoming annual meeting on May 16-19, 2022 at the Walter E. Washington 